Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to share pricing for the Performance Share Plan:
- Ordinary Share price: 1,483 pence
- American Depositary Share (ADS) price: $46.01
Material Changes
The filing details an increase in notional interests in Ordinary Shares and ADSs for various directors and executives. This increase resulted from the notional re-investment of dividends paid to shareholders on July 5, 2012. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports on the administrative update of share plan holdings in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a). It notes that accrued notional dividends will be paid out based on vesting percentages after the relevant three-year measurement period.
Investor Verification Points
- Verify the specific number of Ordinary Shares and ADSs allocated to each named director in the Performance Share Plan.
- Confirm the share price of 1,483 pence and $46.01 per ADS used for the July 5, 2012 dividend reinvestment.
- Review the vesting schedule and conditions for the three-year measurement period to understand future payout potential.